Новые возможности двойной бронходилатационной терапии у пациентов с хронической обструктивной болезнью легких

1. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Updated 2018. Available from http://www.goldcopd.org/ 
2. Авдеев С.Н., Трушенко Н.В. Двойная бронходилатация ‒ новая парадигма длительно терапии хронической обструктивной болезни легких. Практическая пульмонология. 2015;3:24-32. [Avdeev SN, Trushenko NV Dual bronchodilatator therapy – new paradigm for chronic obstructive pulmonary disease treatment Practical pulmonology 2015;3:24-32]
3. Ford ES. Hospital discharges. readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the nationwide inpatient sample 2001–2012 and nationwide emergency department sample 2006–2011. Chest. 2015;147:989-98.
4. Ingebrigtsen TS, Marott JL, Nordestgaard BG, et al. Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population. J Gen Intern Med. 2015;30:51-9.
5. Bender BG. Nonadherence in chronic obstructive pulmonary disease patients: what do we know and what should we do next? Curr Opin Pulm Med. 2014;20:132-7.
6. Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, et al. Translational study searching for synergy between glycopyrronium and indacaterol. COPD. 2014;12:175-81.
7. Сazzola M, Molimard M. The scientific rationale for combining long-acting beta-2-agonists and muscarinic antagonist in COPD. Pulm Pharmacol Ther. 2010;23:257-67.
8. Трофимов В.И., Сорокина Л.Н. Патогенетические основы холинолитической терапии и возможные механизмы ее потенцирования под влиянием β2-адреномиметиков. Пульмонология. 2014;(2):91-9 [Trofimov VI, Sorokina LN. Mechanisms of anticholinergic effects and probable mechanisms of their potentiation using beta-2-agonists. Pulmonology. 2014;2:91-9 (In Russ.)].
9. Van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 2012;21:101-8.
10. Deas SD, Huprikar N. Dual bronchodilatator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and safety of fixed dose combination treatments in the setting of recent guideline updates. Curr Opin Pulm Med. 2018;24:130-7.
11. Авдеев С.Н., Трушенко Н.В. Возможности фиксированной комбинации индакатерола/гликопиррония в терапии ХОБЛ: обзор современных данных. Пульмонология. 2018;28(2):224-33 [Avdeev SN, Trushenko NV. Fixed combination of indacaterol/glycopyrronium for COPD treatment: review. Pulmonology. 2018;28(2):224-33 (In Russ.)].
12. D’Urzo T, Donohue JF, Price D, Miravitlles M, Kerwin E. Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease. Expert Rev Respir Med. 2015:9(5):519-32.
13. Wedzicha JA, Banerji D, Chapman KR Indacaterol-Glycopirronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374:2222-34.
14. Lee JH, Lee YK, Kim EK, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med. 2010;104:542-9. 
15. Miravitlles M, Calle M, Soler-Cataluna JJ. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol. 2012;48:86-98.
16. Maltais F, Singh S, Donald AC, et al. Effects of a combination of umeclidinium/ vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis. 2014;8:169-81.
17. Айсанов З.Р., Авдеев С.Н., Архипов В.В., Белевский А.С., Лещенко И.В., Овчаренко С.И., Шмелев Е.И., Чучалин А.Г. Национальные клинические рекомендации по диагностике и лечению ХОБЛ: алгоритм принятия клинических решений. Пульмонология. 2017;27(1):13-20 [Aisanov ZR, Avdeev SN, Arkhipov VV, Belevskiy AS, Leshchenko IV, Ovcharenko SI, Shmelev EI, Chuchalin AG National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision making algorithm. Pulmonology. 2017;27(1):13-20 (In Russ.)].
18. Sharafkhaneh A, Altan AE, Colice GL, et al. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. Respir Med. 2014;108:1310-20.
19. Авдеев С.Н., Трушенко Н.В. Новые перспективы в лечении хронической обструктивной болезни легких: в фокусе – аклидиния бромид. Пульмонология. 2015;25(6):725-35 [Avdeev SN, Trushenko NV. New perspectives in therapy of chronic obstructive pulmonary disease: revolving around aclidinium bromide. Pulmonology. 2015;25(6):725-35 (In Russ.)].
20. Milara J, Gabarda E, Gavalda A, et al. An assessment of the functional profile of aclidinium in human bronchi and left atria. Eur Respir J. 2011;38:859.
21. Rogliani P, Calzetta L, Ora J, et. al. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. Eur J Pharmacol. 2015;761:383-90.
22. Gavalda A, Ramos I, Carcasona C, et al. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. Pulmonary Pharmacology & Therapeutics. 2014;28:114-21.
23. Lopez-Campos JL, Calero C, Lopez-Ramirez C, et al. Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium. Patient Preference and Adherence. 2015;9:95-104.
24. Kerwin EM, D`Urzo AD, Gelb AF, et al. ACCORD I study investigators. Efficacy and safety of 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9:90-101.
25. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of treatment with twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40:830-36.
26. Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;19.9:CD010509.
27. Verkindre C, Fukuchi Y, Flemale A, et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonists, in COPD patients. Resp Med. 2010;104:1482-9.
28. Watz H, Beeh KM, Magnussen H, et al. Effect of aclidinium bromide on static lung function and hyperinflation in patients with moderate to severe COPD. Eur Respir J. 2013;42:4633.
29. Campbell M, Eliraz A, Johansson G, et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med. 2005;99:1511-20.
30. Cote C, Pearle JL, Sharafkhaneh A, Spangenthal S. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm Pharmacol Ther. 2009;22:44-9.
31. Derom E, Strandgården K, Schelfhout V, Borgström L, Pauwels R. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD. Respir Med. 2007;101:1931-41.
32. D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/ formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123. 
33. Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). Available from: https://clinicaltrials.gov/ct2/ show/NCT01437397
34. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/ formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178.
35. Авдеев С.Н. Схемы терапии Беродуалом при хронической обструктивной болезни легких: при развитии обострений и в стабильный период. Практическая пульмонология. 2014;3:20-5 [Avdeev SN. Scheme of therapy with Berodual for stable chronic obstructive pulmonary disease and exacerbations. Practical pulmonology. 2014;3:20-5 (In Russ.)].
36. Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D. Gil EG ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J COPD. 2017;12:2545-58.
37. Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189:250-5. 
38. Agusti A, Hedner J, Marin JM, et al. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev. 2011;20:183-94.
39. Kim YJ, Lee BK, Jung CY, et al. Patient’s perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL Study. Korean J Intern Med. 2012;27:426-35. 
40. Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res. 2013;14:112. 
41. Lange P, Marott JL, Vestbo J, Nordestgaard BG. Prevalence of night-time dyspnoea in COPD and its implications for prognosis. Eur Respir J. 2014;43:1590-8.
42. Price D, Small M, Milligan G, et al. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J COPD. 2013;8:595-603.
43. Miravitlles M, Chapman KR, Chuecos F, Ribera A, Gil EG. The efficacy of aclidinium/formoterol on lumg function and symptoms in patients with COPD categorized by symptom status: a pooled analysis. Int J COPD. 2016;11:2041-53. 
44. Waschki B, Spruit MA, Watz H, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med. 2012;106:522-30. 
45. Demeyer H, Louvaris Z, Frei A, et al. Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial. Thorax. 2017;72:415-23.
46. Donaire-Gonzalez D, Gimeno-Santos E, Balcells E, et al. Benefits of physical activity on COPD hospitalisation depend on intensity. Eur Respir J. 2015;46:1281-9. 
47. Waschki B, Kirsten AM, Holz O, et al. Disease progression and changes in physical activity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:295-306. 
48. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140:331-42. 
49. Troosters T, van der Molen T, Polkey M, et al. Improving physical activity in COPD: towards a new paradigm. Respir Res. 2013;14:115.
50. Demeyer H, Burtin C, Hornikx M, et al. The minimal important difference in physical activity in patients with COPD. PLoS One. 2016;11:e0154587.
51. Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M et al. Efficacy and safety of aclidinium/formrterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48:1030-9.
52. Medic G, Lindner L, van der Weijden M, Karabis A. Efficacy and safety of aclidinium/formoterol versus tiotropium in COPD: results of an indirect treatment comparison. Adv Ther. 2016;33:379-99. 
53. Make B. Safety and tolerability of fixed-dose combination aclidinium bromide/formoterol fumarate: results of two 6-month studies in patients with moderate to severe COPD. Am J Respir Crit Care Med. 2014;189:A6009.
54. Donohue JF, Soong W, et al. Lung function and safety of aclidinium bromide/formoterol fumarate fixed-dose combination: results of a 1-year trial in patients with COPD. Respir Med. 2016;116:41-8.
55. Jones P.W. Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease. Int J COPD. 2015;10:677-87. 
56. Kruger P, Ehrlein B, Zier M, Greguletz R. Inspiratory flow resistance of marketed dry powder inhalers (DPI). Eur Resp J. 2014;44:Suppl 58.
57. Newman SP, Sutton DJ, Segarra R, Lamarca R, de Miquel G. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009;78:322-8.
58. Block K, Fyrnys B. Impact of different inhalation volumes on the aerodynamics of aclidinium bromide delivered through the Genuair® inhaler. Am J Crit Care Med. 2010;181:A4467.
59. Magnussen H, Watz H, Zimmermann I, et al. Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med. 2009;103:1832-7.
60. Chrystyn H, Niederlaender C. The Genuair inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract. 2012;66(3):309-17. 
61. Marth K, Schuller E, Pohl W. Improvements in patient-reported outcomes: a prospective, non-interventional study with aclidinium bromide for treatment of COPD. Respir Med. 2015;109:616-24.
62. Leidy NK, Wilcox TK, Jones PW, et al. EXACT-PRO Study Group. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. Am J Resp Crit Care Med. 2011;183:323-9.
63. van der Palen J, Ginko T, Kroker A. Et al. Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opin Drug Deliv. 2013;10:1023-31.

________________________________________________

1. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Updated 2018. Available from http://www.goldcopd.org/ 
2. Avdeev SN, Trushenko NV Dual bronchodilatator therapy – new paradigm for chronic obstructive pulmonary disease treatment Practical pulmonology 2015;3:24-32
3. Ford ES. Hospital discharges. readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the nationwide inpatient sample 2001–2012 and nationwide emergency department sample 2006–2011. Chest. 2015;147:989-98.
4. Ingebrigtsen TS, Marott JL, Nordestgaard BG, et al. Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population. J Gen Intern Med. 2015;30:51-9.
5. Bender BG. Nonadherence in chronic obstructive pulmonary disease patients: what do we know and what should we do next? Curr Opin Pulm Med. 2014;20:132-7.
6. Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, et al. Translational study searching for synergy between glycopyrronium and indacaterol. COPD. 2014;12:175-81.
7. Сazzola M, Molimard M. The scientific rationale for combining long-acting beta-2-agonists and muscarinic antagonist in COPD. Pulm Pharmacol Ther. 2010;23:257-67.
8. Trofimov VI, Sorokina LN. Mechanisms of anticholinergic effects and probable mechanisms of their potentiation using beta-2-agonists. Pulmonology. 2014;2:91-9 (In Russ.)
9. Van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 2012;21:101-8.
10. Deas SD, Huprikar N. Dual bronchodilatator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and safety of fixed dose combination treatments in the setting of recent guideline updates. Curr Opin Pulm Med. 2018;24:130-7.
11. Avdeev SN, Trushenko NV. Fixed combination of indacaterol/glycopyrronium for COPD treatment: review. Pulmonology. 2018;28(2):224-33 (In Russ.)
12. D’Urzo T, Donohue JF, Price D, Miravitlles M, Kerwin E. Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease. Expert Rev Respir Med. 2015:9(5):519-32.
13. Wedzicha JA, Banerji D, Chapman KR Indacaterol-Glycopirronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374:2222-34.
14. Lee JH, Lee YK, Kim EK, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med. 2010;104:542-9. 
15. Miravitlles M, Calle M, Soler-Cataluna JJ. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol. 2012;48:86-98.
16. Maltais F, Singh S, Donald AC, et al. Effects of a combination of umeclidinium/ vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis. 2014;8:169-81.
17. Aisanov ZR, Avdeev SN, Arkhipov VV, Belevskiy AS, Leshchenko IV, Ovcharenko SI, Shmelev EI, Chuchalin AG National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision making algorithm. Pulmonology. 2017;27(1):13-20 (In Russ.)
18. Sharafkhaneh A, Altan AE, Colice GL, et al. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. Respir Med. 2014;108:1310-20.
19.Avdeev SN, Trushenko NV. New perspectives in therapy of chronic obstructive pulmonary disease: revolving around aclidinium bromide. Pulmonology. 2015;25(6):725-35 (In Russ.)
20. Milara J, Gabarda E, Gavalda A, et al. An assessment of the functional profile of aclidinium in human bronchi and left atria. Eur Respir J. 2011;38:859.
21. Rogliani P, Calzetta L, Ora J, et. al. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. Eur J Pharmacol. 2015;761:383-90.
22. Gavalda A, Ramos I, Carcasona C, et al. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. Pulmonary Pharmacology & Therapeutics. 2014;28:114-21.
23. Lopez-Campos JL, Calero C, Lopez-Ramirez C, et al. Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium. Patient Preference and Adherence. 2015;9:95-104.
24. Kerwin EM, D`Urzo AD, Gelb AF, et al. ACCORD I study investigators. Efficacy and safety of 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9:90-101.
25. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of treatment with twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40:830-36.
26. Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;19.9:CD010509.
27. Verkindre C, Fukuchi Y, Flemale A, et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonists, in COPD patients. Resp Med. 2010;104:1482-9.
28. Watz H, Beeh KM, Magnussen H, et al. Effect of aclidinium bromide on static lung function and hyperinflation in patients with moderate to severe COPD. Eur Respir J. 2013;42:4633.
29. Campbell M, Eliraz A, Johansson G, et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med. 2005;99:1511-20.
30. Cote C, Pearle JL, Sharafkhaneh A, Spangenthal S. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm Pharmacol Ther. 2009;22:44-9.
31. Derom E, Strandgården K, Schelfhout V, Borgström L, Pauwels R. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD. Respir Med. 2007;101:1931-41.
32. D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/ formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123. 
33. Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). Available from: https://clinicaltrials.gov/ct2/ show/NCT01437397
34. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/ formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178.
35. Avdeev SN. Scheme of therapy with Berodual for stable chronic obstructive pulmonary disease and exacerbations. Practical pulmonology. 2014;3:20-5 (In Russ.)
36. Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D. Gil EG ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J COPD. 2017;12:2545-58.
37. Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189:250-5. 
38. Agusti A, Hedner J, Marin JM, et al. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev. 2011;20:183-94.
39. Kim YJ, Lee BK, Jung CY, et al. Patient’s perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL Study. Korean J Intern Med. 2012;27:426-35. 
40. Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res. 2013;14:112. 
41. Lange P, Marott JL, Vestbo J, Nordestgaard BG. Prevalence of night-time dyspnoea in COPD and its implications for prognosis. Eur Respir J. 2014;43:1590-8.
42. Price D, Small M, Milligan G, et al. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J COPD. 2013;8:595-603.
43. Miravitlles M, Chapman KR, Chuecos F, Ribera A, Gil EG. The efficacy of aclidinium/formoterol on lumg function and symptoms in patients with COPD categorized by symptom status: a pooled analysis. Int J COPD. 2016;11:2041-53. 
44. Waschki B, Spruit MA, Watz H, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med. 2012;106:522-30. 
45. Demeyer H, Louvaris Z, Frei A, et al. Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial. Thorax. 2017;72:415-23.
46. Donaire-Gonzalez D, Gimeno-Santos E, Balcells E, et al. Benefits of physical activity on COPD hospitalisation depend on intensity. Eur Respir J. 2015;46:1281-9. 
47. Waschki B, Kirsten AM, Holz O, et al. Disease progression and changes in physical activity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:295-306. 
48. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140:331-42. 
49. Troosters T, van der Molen T, Polkey M, et al. Improving physical activity in COPD: towards a new paradigm. Respir Res. 2013;14:115.
50. Demeyer H, Burtin C, Hornikx M, et al. The minimal important difference in physical activity in patients with COPD. PLoS One. 2016;11:e0154587.
51. Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M et al. Efficacy and safety of aclidinium/formrterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48:1030-9.
52. Medic G, Lindner L, van der Weijden M, Karabis A. Efficacy and safety of aclidinium/formoterol versus tiotropium in COPD: results of an indirect treatment comparison. Adv Ther. 2016;33:379-99. 
53. Make B. Safety and tolerability of fixed-dose combination aclidinium bromide/formoterol fumarate: results of two 6-month studies in patients with moderate to severe COPD. Am J Respir Crit Care Med. 2014;189:A6009.
54. Donohue JF, Soong W, et al. Lung function and safety of aclidinium bromide/formoterol fumarate fixed-dose combination: results of a 1-year trial in patients with COPD. Respir Med. 2016;116:41-8.
55. Jones P.W. Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease. Int J COPD. 2015;10:677-87. 
56. Kruger P, Ehrlein B, Zier M, Greguletz R. Inspiratory flow resistance of marketed dry powder inhalers (DPI). Eur Resp J. 2014;44:Suppl 58.
57. Newman SP, Sutton DJ, Segarra R, Lamarca R, de Miquel G. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009;78:322-8.
58. Block K, Fyrnys B. Impact of different inhalation volumes on the aerodynamics of aclidinium bromide delivered through the Genuair® inhaler. Am J Crit Care Med. 2010;181:A4467.
59. Magnussen H, Watz H, Zimmermann I, et al. Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med. 2009;103:1832-7.
60. Chrystyn H, Niederlaender C. The Genuair inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract. 2012;66(3):309-17. 
61. Marth K, Schuller E, Pohl W. Improvements in patient-reported outcomes: a prospective, non-interventional study with aclidinium bromide for treatment of COPD. Respir Med. 2015;109:616-24.
62. Leidy NK, Wilcox TK, Jones PW, et al. EXACT-PRO Study Group. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. Am J Resp Crit Care Med. 2011;183:323-9.
63. van der Palen J, Ginko T, Kroker A. Et al. Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opin Drug Deliv. 2013;10:1023-31.

С.Н. Авдеев 1,2, Н.В. Трушенко 1,2

1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБУ «Научно-исследовательский институт пульмонологии» ФМБА России, Москва, Россия

________________________________________________

S.N. Avdeev 1,2, N.V. Trushenko 1,2

1 I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia;
2 Pulmonology Scientific Research Institute under Federal Medical and Biological Agency of Russian Federation, Moscow, Russia